BD (NYSE:BDX) announced today that it still expects the spinoff of its diabetes business — named Embecta — to complete on April 1.
Franklin Lakes, N.J.-based BD announced in May 2021 that it intended to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it unveiled the name of the new business as “Embecta.”
Get the full story at our sister site, Drug Delivery Business News.